Case: 21-1262 Document: 64 Page: 1 Filed: 12/29/2021
NOTE: This order is nonprecedential.
United States Court of Appeals
for the Federal Circuit
______________________
SANOFI-AVENTIS U.S. LLC, SANOFI-AVENTIS
DEUTSCHLAND GMBH, SANOFI WINTHROP
INDUSTRIE,
Plaintiffs-Appellants
v.
MYLAN GMBH, BIOCON LTD., BIOCON
RESEARCH LTD., BIOCON SDN.BHD, BIOCON
S.A.,
Defendants-Appellees
______________________
2021-1262
______________________
Appeal from the United States District Court for the
District of New Jersey in No. 2:17-cv-09105-SRC-CLW,
Judge Stanley R. Chesler.
______________________
SUA SPONTE
______________________
Before DYK, CLEVENGER, and TARANTO, Circuit Judges.
PER CURIAM.
ORDER
Case: 21-1262 Document: 64 Page: 2 Filed: 12/29/2021
2 SANOFI-AVENTIS U.S. LLC v. MYLAN GMBH
Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland
GmbH, Sanofi Winthrop Industrie (collectively, “Sanofi”)
filed a patent infringement suit against Mylan GmbH, Bi-
ocon Ltd., Biocon Research Ltd., Biocon Sdn.Bhd., and Bi-
ocon S.A. (collectively, “Mylan”) in the District Court for
the District of New Jersey asserting Mylan infringed
claims 21, 22, 25, and 30 of Sanofi’s U.S. Patent No.
9,526,844 (“the ’844 Patent”). The district court found no
infringement of the asserted claims and that the asserted
claims are invalid for lack of written description. Sanofi ap-
peals.
We affirmed today in a related appeal, Sanofi-Aventis
U.S. LLC, et al. v. Mylan GmbH, et al., No. 2020-2068, the
final written decision by the U.S. Patent Trial and Appeal
Board in IPR2018-01680 holding that claims 21–30 of the
’844 Patent would have been unpatentable as anticipated
and/or obvious. Accordingly, Sanofi’s appeal from the dis-
trict court’s ruling is moot.
IT IS ORDERED THAT:
Sanofi’s appeal in Appeal No. 2021-1262 is dismissed
as moot.
FOR THE COURT
December 29, 2021 /s/ Peter R. Marksteiner
Date Peter R. Marksteiner
Clerk of Court